Autopsy report · NCT00594555

A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia

“Principal Investigator resigned position with the University of Cincinnati, closing study at this site will reopen study in new position”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University of Cincinnati

Sponsor type

University, hospital or other

Conditions

Chronic Myeloid Leukemia, Blast Crisis; Acute Myeloid Leukemia

Interventions

Imatinib Mesylate; CLAG

Participants

20 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Wearable Auscultation Device Validation in Children
  “The Principal Investigator is departing from the study site.” (74% match in meaning)
• CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction
  “Principal Investigator resigned and closed program” (72% match in meaning)
• Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis
  “Due to the principal investigator leaving the institution and slow enrollment, we have decided to close the study prior to study completion” (72% match in meaning)
• Brain Function in Depression and Insulin Resistance
  “Principal Investigator Left University” (70% match in meaning)
• Surgical Field Bacterial Contamination in Primary Total Hip (THA) and Knee (TKA) Arthroplasty
  “Study principal investigator left the organization” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.